AVANOVA – click here for more details

ENGOT-OV24-NSGO/AVANOVA, EudraCT number: 2014-004269-26, Version 2.0

Part 2: AVANOVA2 – A three-arm, open-label, phase II randomized study to evaluate the efficacy of niraparib and/or niraparib-bevacizumab combination against bevacizumab alone in Women with HRD platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.


FANDANGO – more details upcoming

ENGOT-EN1/FANDANGO, EudraCT number: 2016–000193-38, Version 1.3

A randomised phase II trial of first-line combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer.


PALEO – more details upcoming

ENGOT-EN3-NSGO/PALEO, EudraCT number: 2016-001848-20, Version 1.0

A randomized phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.